Skip to content

Hereditary Hepatorenal Tyrosinemia Natural History in Egypt and the Arab World (Multicenter Clinical Study)

Hereditary Hepatorenal Tyrosinemia Natural History (Multicenter Clinical Study): Registry for Patients With Tyrosinemia Type I in Egypt and the Arab World

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03446586
Enrollment
50
Registered
2018-02-27
Start date
2019-04-05
Completion date
2023-12-31
Last updated
2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Tyrosinemia, Type I

Brief summary

The purpose of the registry/repository is to understand the natural history of tyrosinemia in our region and to provide a mechanism to store data and specimens to support the conduct of future research about hereditary tyrosinemia among the Arabs.

Detailed description

The purpose of this study is to create an electronic registry of phenotypic, laboratory information, treatment and outcomes options for tyrosinemia type I. The registry is longitudinal in nature including retrospective clinical data from birth to the most recent encounter with all data entered in chronological fashion. The goals of this registry are the better understanding of the natural history and treatment outcomes of these patients and to determine/evaluate biochemical and clinical parameters for monitoring and prognosis of tyrosinemia type I.

Interventions

None listed

Sponsors

Society of Friends of Liver Patients in the Arab World (SLPAW)
CollaboratorUNKNOWN
Yassin Abdelghaffar Charity Center for Liver Disease and Research
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Biochemical or molecular diagnosis of Tyrosinemia Type I. 2. Examined/followed by one of the participating sites. 3. Parental/guardian permission (informed consent) for participation.

Exclusion criteria

1. Diagnosis of tyrosinemia has been excluded. 2. Not examined/followed by one of the participating sites. 3. Unwilling to provide informed consent for participation.

Design outcomes

Primary

MeasureTime frameDescription
Create a registry for tyrosinemia type I.5 YearsThis outcome is a binary 'yes/no' outcome as to whether or not this study can successfully create a repository with the intent to store data and specimens to support the conduct of future research on tyrosinemia type I.

Countries

Egypt

Contacts

Primary ContactMamdouh A. Ahmed
dr.yassinabdelghaffar@gmail.com02-01221707770

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026